Table 2.
HPV Detection of Genotype Prevalence by Onclarity Across Age Groups in Patients 30 Years or Older With NILM Cytology
| Age Group, No. (%) | ||||
|---|---|---|---|---|
| HPV Result | 30-39 y (n = 8,663) | 40-49 y (n = 6,829) | ≥50 y (n = 6,792) | Overall (n = 22,284) |
| Overall HPV | 889 (10.3) | 485 (7.1) | 387 (5.7) | 1,761 (7.9) |
| HPV 16 | 173 (2.0) | 77 (1.1) | 80 (1.2) | 330 (1.5) |
| HPV 18 | 41 (0.5) | 29 (0.4) | 23 (0.3) | 93 (0.4) |
| HPV 45 | 63 (0.7) | 34 (0.5) | 18 (0.3) | 115 (0.5) |
| HPV 16/18 | 214 (2.5) | 106 (1.6) | 103 (1.5) | 423 (1.9) |
| HPV 18/45 | 104 (1.2) | 63 (0.9) | 41 (0.6) | 208 (0.9) |
| HPV 16/18/45 | 277 (3.2) | 140 (2.1) | 121 (1.8) | 538 (2.4) |
| Other 11 GTs | 612 (7.1) | 345 (5.1) | 266 (3.9) | 1,223 (5.5) |
| HPV negative | 7,774 (89.7) | 6,344 (92.9) | 6,405 (94.3) | 20,523 (92.1) |
| HC2 positive | 773/8,644 (8.9) | 421/6,814 (6.2) | 331/6,774 (4.9) | 1,525/22,232 (6.9) |
GT, genotype; HC2, digene Hybrid Capture 2 assay; HPV, human papillomavirus; NILM, negative for intraepithelial lesion or malignancies.